Porfimer sodium - Pinnacle Biologics
Alternative Names: CL 184116; Photobarr; Photofrin; Photofrin II; Photofrin PDT; Photofrin Photodynamic Therapy - Axcan PharmaLatest Information Update: 24 Oct 2021
At a glance
- Originator QLT
- Developer Adare Pharmaceuticals; Novelion Therapeutics; Pinnacle Biologics; Roswell Park Cancer Institute; University of Pennsylvania
- Class Antineoplastics; Hematoporphyrins
- Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bladder cancer; Cervical cancer; Cervical dysplasia; Gastric cancer; High-grade oesophageal dysplasia; Non-small cell lung cancer; Oesophageal cancer
- Phase II Malignant-mesothelioma
- No development reported Brain cancer; Pancreatic cancer
- Discontinued Cholangiocarcinoma; Glioblastoma
Most Recent Events
- 12 Apr 2021 Discontinued - Phase-III for Cholangiocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Switzerland, South Korea, Canada, Germany (IV)
- 09 Apr 2021 Discontinued - Phase-II for Glioblastoma (Second-line therapy or greater) in USA (IV)
- 22 Mar 2019 Concordia Laboratories completes a phase I trial for Non-small cell lung cancer in USA (NCT03344861)